TG Therapeutics Inc (NASDAQ: TGTX) has reported earnings for its second fiscal quarter (ending June 30) of $0.05 versus a loss $-0.34 for the same period a year ago. Relative to the consensus estimate of $-0.04, this was a premium of $0.09. For the latest four quarters through June 30, E.P.S. were $0.67 versus $-1.27 for the same period a year ago.
Recent Price Action
TG Therapeutics Inc (NASDAQ: TGTX) stock enjoyed a major increase of 19.6% on 8/6/24. The shares closed at $20.58. Moreover, trading volume in this advance was exceptionally high at 377% of normal. The stock has been exceptionally strong relative to the market over the last nine months and has risen 3.9% during the last week.
Current PriceTarget Research Rating
TGTX is expected to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
TG Therapeutics has a current Value Trend Rating of A (Highest Rating). This rating combines highly consistent signals from two proprietary PTR measures of a stock’s attractiveness. TG Therapeutics has a very high Power Rating of 87 and a very high Appreciation Score of 94, leading to the Highest Value Trend Rating.
Rating Review
In light of this new information and very positive price change we are reviewing our current Overall Rating of A. This review will be completed in the next several days.
Be the first to comment